Jounce Therapeutics

company

About

Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.

  • 101 - 250

Details

Last Funding Type
Series B
Last Funding Money Raised
$56M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
101 - 250
Operating Status
Active

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive
significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$56M
Jounce Therapeutics has raised a total of $56M in funding over 2 rounds. Their latest funding was raised on Apr 23, 2015 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 23, 2015 Series B $56M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Jounce Therapeutics is funded by 1 investors. Inbio Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Inbio Ventures Series B